INCOME
|
| |
Core funding (corporate) |
€ 329.500,00 |
52,90% |
| |
Membership fees |
€ 18.000,00 |
2,89% |
| |
EFA Projects |
€ 180.000,00 |
28,90% |
| |
EU Projects |
€ 92.590,43 |
14,87% |
| |
Regularisation |
€ 2.737,98 |
0,44% |
| |
TOTAL
|
€ 622.828,41
|
|
Acknowledgements
OPERATING PROGRAMME
|
| |
Grants |
€ 329.500,00 |
|
| |
AirLiquide |
€ 30.000,00 |
9,10% |
| |
AlkAbello |
€ 30.000,00 |
9,10% |
| |
AstraZeneca |
€ 30.000,00 |
9,10% |
| |
Boehringer Ingelheim |
€ 30.000,00 |
9,10% |
| |
Chiesi |
€ 5.000,00 |
1,52% |
| |
GSK |
€ 30.000,00 |
9,10% |
| |
Novartis |
€ 35.000,00 |
10,62% |
| |
TEVA |
€ 30.000,00 |
9,10% |
| |
Stallergenes |
€ 30.000,00 |
9,10% |
| |
Roche |
€ 30.000,00 |
9,10% |
| |
SigAirHandling |
€ 15.000,00 |
4,55% |
| |
LindeGas |
€ 4.500,00 |
1,37% |
| |
Sanofi |
€ 30.000,00 |
9,10% |
| |
|
|
|
PROJECT PROGRAMME
|
| |
EFA Projects |
€ 180.000,00 |
|
Asthma Programme
|
| |
Astra Zeneca |
€ 19.000,00 |
10,56% |
| |
Novartis |
€ 19.000,00 |
10,56% |
| |
GSK |
€ 19.000,00 |
10,56% |
| |
TEVA |
€ 19.000,00 |
10,56% |
Capacity Building
|
| |
TEVA |
€ 30.000,00 |
16,67% |
| |
Boehringer Ingelheim |
€ 28.000,00 |
15,56% |
Interest Group EP
|
| |
Novartis |
€ 8.000,00 |
4,44% |
| |
ALK Abello |
€ 8.000,00 |
4,44% |
CRD Campaign
|
| |
Novartis |
€ 30.000,00 |
16,67% |